PCSK9 and metabolic dysfunction-associated steatotic liver disease: Thus, although PCSK9 inhibitors have been mainly developed for the treatment of hypercholesterolemia [218], early studies have shown that PCSK9 inhibitors could reduce steatosis biomarkers in some patients with both familiar hypercholesterolemia and NAFLD [221].